InnoCare orelabrutinib data presented in three JSH 2026 oral sessions
InnoCare Pharma has presented three studies of orelabrutinib, its selective BTK inhibitor, in oral sessions at the 88th Annual Meeting of the Japanese Society of Hematology (JSH 2026), held in Kyoto from 9 to 11 October. The datasets span a real-world chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) cohort, a Phase 2 chemo-free combination in marginal zone lymphoma (MZL), and a Phase 2 regimen designed for elderly and frail diffuse large B cell lymphoma (DLBCL) patients.
The conference appearances reinforce InnoCare's strategy of building a data package for orelabrutinib outside China. JSH is the primary scientific forum for Japanese haematology and represents a meaningful step towards broadening the drug's geographic credibility in a market where BTK inhibitors are already well-established competitors.
CLL/SLL real-world outcomes
The largest dataset comprised a retrospective, multicentre study of 211 Chinese patients treated with orelabrutinib monotherapy across first-line and relapsed/refractory settings. At a median follow-up of 33.5 months, neither median progression-free survival (PFS) nor median overall survival (OS) had been reached. The 36-month PFS rate was 80.0% and the 36-month OS rate was 91.3%. Patients who initiated orelabrutinib in the first or second line achieved a 36-month PFS of 81.8%, compared with 70.3% for those starting at the third line or beyond, a difference the investigators described as suggesting earlier initiation may be advantageous. The study also reported a manageable safety profile, though specific adverse-event rates were not disclosed in the release.
Phase 2 combination results in MZL and DLBCL
In newly diagnosed MZL, the chemo-free triplet of orelabrutinib, zebetuzumab, and lenalidomide produced an overall response rate of 100% and a complete response rate of 62.5% after six induction cycles in evaluable patients. Of those who were minimal residual disease (MRD)-positive at baseline, 70% achieved MRD negativity by the end of induction. Recruitment remains ongoing and the primary endpoint is three-year PFS, so these results are preliminary.
For elderly and frail DLBCL patients, the combination of orelabrutinib, polatuzumab vedotin, and rituximab produced a complete response rate of 91.7% and an overall response rate of 95.8% in patients completing six cycles of efficacy assessment. The median patient age was 78, with 43.6% aged over 80 and 74.3% carrying comorbidities. At a median follow-up of seven months, median PFS and OS had not been reached, and the estimated nine-month PFS rate was 92.8%. No new safety signals were identified.
Competitive and regulatory context
The BTK inhibitor class is crowded. Ibrutinib, acalabrutinib, and zanubrutinib are all approved in multiple B cell malignancies across major markets. Zanubrutinib, developed by BeiGene, is particularly pertinent as a Chinese-origin BTK inhibitor that has already secured approvals in the US, Europe, and Japan. For orelabrutinib, which holds approvals in China for CLL/SLL, mantle cell lymphoma, and Waldenstrom macroglobulinaemia, the immediate priority appears to be generating real-world and combination data that differentiate it from established rivals, particularly in underserved populations such as frail elderly DLBCL patients where standard chemoimmunotherapy carries prohibitive toxicity.
InnoCare has not announced regulatory submissions in Japan or Western markets, and the company did not provide a timeline for any such filings in the JSH release. Investors will be watching whether the Phase 2 MZL and DLBCL datasets mature into pivotal programmes, and whether the company seeks a partnership to fund ex-China commercialisation.